How many drugs treat Acute myeloid leukemia, disease?

Drug Landscape tracks 10 marketed treatments for Acute myeloid leukemia, disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-myeloid-leukemia-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Acute myeloid leukemia, disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute myeloid leukemia, disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute myeloid leukemia, disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vanflyta	QUIZARTINIB	Daiichi Sankyo Inc		Macrophage colony-stimulating factor 1 receptor	2023-01-01
Rezlidhia	OLUTASIDENIB	Rigel Pharms		mutated IDH1	2022-01-01
Daurismo	Glasdegib Maleate	Pfizer	Hedgehog pathway inhibitor	Smoothened (transmembrane protein)	2018-01-01
Daurismo	glasdegib	Pfizer	Hedgehog Pathway Inhibitor [EPC]	Smoothened homolog	2018-01-01
Tibsovo	IVOSIDENIB	Servier	Isocitrate Dehydrogenase 1 Inhibitor [EPC]	mutant IDH1	2018-01-01
Xospata	GILTERITINIB	Astellas Pharma		Leukocyte tyrosine kinase receptor	2018-01-01
Idhifa	ENASIDENIB	Bristol-Myers Squibb	Isocitrate Dehydrogenase 2 Inhibitor	Isocitrate dehydrogenase [NADP], mitochondrial	2017-01-01
Rydapt	MIDOSTAURIN	Novartis	Kinase Inhibitor [EPC]	Mast/stem cell growth factor receptor Kit	2017-01-01
Venclexta	venetoclax	AbbVie	BCL-2 Inhibitor [EPC]	Apoptosis regulator Bcl-2	2014-01-01
Dacogen	decitabine	Sun Pharma	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Acute myeloid leukemia, disease
· 4 drugs in Acute myeloid leukemia, disease
Bristol-Myers Squibb · 2 drugs in Acute myeloid leukemia, disease
Assistance Publique Hopitaux De Marseille · 1 drug in Acute myeloid leukemia, disease
Eli Lilly · 1 drug in Acute myeloid leukemia, disease
Celyad Oncology SA · 1 drug in Acute myeloid leukemia, disease
Azienda Ospedaliera San Giovanni Battista · 1 drug in Acute myeloid leukemia, disease
Chipscreen Biosciences, Ltd. · 1 drug in Acute myeloid leukemia, disease
Chiron · 1 drug in Acute myeloid leukemia, disease
Daiichi Sankyo Inc · 1 drug in Acute myeloid leukemia, disease
Chinese PLA General Hospital · 1 drug in Acute myeloid leukemia, disease
Astellas Pharma · 1 drug in Acute myeloid leukemia, disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute myeloid leukemia, disease:

Cite this brief

Drug Landscape (2026). Acute myeloid leukemia, disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-myeloid-leukemia-disease. Accessed 2026-06-09.

Acute myeloid leukemia, disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing